(Cefiderocol + xeruborbactam) is under clinical development by Qpex Biopharma and currently in Phase I for Gram-Negative Bacterial Infections. According to GlobalData, Phase I drugs for Gram-Negative Bacterial Infections have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Cefiderocol + xeruborbactam)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Cefiderocol + xeruborbactam) overview
The fixed dose combination of cefiderocol and xeruborbactam is under development for the treatment of antimicrobial resistance (AMR) various infections caused by multi-drug resistant gram-negative bacteria. The drug candidate is administered through intravenous route, and it acts by targeting penicillin-binding protein (PBP) and beta-lactamase.
Qpex Biopharma overview
Qpex Biopharma, a subsidiary of Shionogi Inc, is a biopharmaceutical company that focuses on developing innovative products for infectious diseases. Its main activities include understanding and overcoming resistance mechanisms to improve patient care in both inpatient and outpatient settings. The company specializes in the discovery, development, and regulatory approval of anti-infective medicines, particularly targeting antimicrobial resistance. Qpex Biopharma’s pipeline products include ORAvance, OMNIvance and others. Its ORAvance, an oral treatment beta-lactamase inhibitor targeting extended-spectrum beta-lactamase (ESBL) and carbapenem-resistant Enterobacteriaceae (CRE) infections; OMNIvance drug against infections caused due to acinetobacter, pseudomonas, and Enterobacteriaceae. The company operates in the US. Qpex Biopharma is headquartered in San Diego, California, the US.
For a complete picture of (Cefiderocol + xeruborbactam)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
